Profiling the safety and tolerability of bisphosphonates
- 1 October 2004
- journal article
- review article
- Published by Elsevier in Seminars in Oncology
- Vol. 31, 73-78
- https://doi.org/10.1053/j.seminoncol.2004.07.030
Abstract
No abstract availableKeywords
This publication has 21 references indexed in Scilit:
- American Society of Clinical Oncology 2003 Update on the Role of Bisphosphonates and Bone Health Issues in Women With Breast CancerJournal of Clinical Oncology, 2003
- Zoledronic Acid Versus Placebo in the Treatment of Skeletal Metastases in Patients With Lung Cancer and Other Solid Tumors: A Phase III, Double-Blind, Randomized Trial—The Zoledronic Acid Lung Cancer and Other Solid Tumors Study GroupJournal of Clinical Oncology, 2003
- Toxic acute tubular necrosis following treatment with zoledronate (Zometa)Kidney International, 2003
- Extended Safety Profile of Oral Clodronate After Long-Term Use in Primary Breast Cancer PatientsDrug Safety, 2003
- Efficacy of Zoledronic Acid and Pamidronate in Breast Cancer Patients: A Comparative Analysis of Randomized Phase III TrialsAmerican Journal of Clinical Oncology, 2002
- Randomized, Placebo-Controlled Trial of Clodronate in Patients With Primary Operable Breast CancerJournal of Clinical Oncology, 2002
- Dosing regimens and main adverse events of bisphosphonatesSeminars in Oncology, 2001
- Treatment of Metastatic Bone Disease in Breast Cancer: BisphosphonatesClinical Breast Cancer, 2000
- American Society of Clinical Oncology Guideline on the Role of Bisphosphonates in Breast CancerJournal of Clinical Oncology, 2000
- Oral clodronate in breast cancer patients with bone metastases: a randomized studyJournal of Internal Medicine, 1999